Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT03850301

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

Sponsor: Imperial College London

View on ClinicalTrials.gov

Summary

In multiple sclerosis (MS) cells of the immune system attack the brain causing tissue damage. In secondary progressive MS (SPMS) these repeated immune attacks have stopped but despite this new damage continues to appear. TSPO is a protein found in the brain and cells of the immune system, whose levels increase during MS. The investigators would like to know whether drugs that bind TSPO could dampen the immune responses in patients with SPMS. The investigators will be testing two drugs that affect TSPO; etifoxine and XBD173. Subjects with SPMS will be recruited from neurology clinics at hospitals associated with Imperial College Healthcare NHS Trust. Healthy volunteers will also be recruited in order to provide a comparison to these patients. The volunteers recruited will be invited to the clinical research facility (CRF) at Hammersmith Hospital. The volunteers will take one of the two drugs every day for 7 days. The researchers will perform blood tests before the first dose and after the last dose to investigate the effects of the drugs, including the expression of genes and immune cell activity. This will allow the researchers to explore which of the two drugs produces the greatest changes in the amount of TSPO in the blood in MS patients relative to healthy controls.

Official title: An Experimental Medicine Study to Validate the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target in Multiple Sclerosis

Key Details

Gender

All

Age Range

35 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2018-01-01

Completion Date

2025-01-31

Last Updated

2024-10-15

Healthy Volunteers

Yes

Conditions

Multiple Sclerosis

Interventions

DRUG

XBD173

7 days treatment

DRUG

Etifoxine

7 days treatment

Inclusion Criteria: 1. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. 2. Aged 35-65 years old 3. A female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day) and willing to use one of the contraception methods listed below 4. Male subject must agree to use one of the contraception methods listed above. 5. Willing to abstain from alcohol for the duration of dosing. 6. Expanded Disability Status Scale (EDSS) \>3.5 \<6.5 (SPMS patients only) Exclusion Criteria: 1. History of active neurological disease other than migraine or MS 2. Clinically meaningful abnormalities in routine bloods including: * eGFR \< 60ml/min * Elevation of liver enzymes/bilirubin * Prolonged prothrombin time * Thrombocytopenia 3. Use of the following medications or therapies: * Immunosuppressive or immunomodulatory drugs within the last 6 months * Alemtuzumab or haematopeotic stem cell therapy * Central nervous system depressants (including opioid analgesics, barbiturates, sleeping pills, antihistamines, antipsychotics) * P450 CY3A4 inducers or inhibitors * oral contraceptives * oral anticoagulants or antiplatelet agents other than low dose aspirin * levothyroxine 4. Currently breastfeeding 5. Any clinical significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures. 6. History of any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study, such as some chronic systemic diseases affecting blood, liver or kidneys or endocrine system 7. Unwillingness or inability to follow the procedures outlined in the protocol 8. Subject is mentally or legally incapacitated 9. Contraindication to XBD173 use: • Hypersensitivity to the active substance or to any of the excipients 10. Contraindication to etifoxine use: * Myasthenia gravis * syndromes of glucose and galactose malabsorption or lactose deficiency

Locations (1)

Imperial College Healthcare NHS Trust

London, England, United Kingdom